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Summary
Background Despite recent improvements in prevention, diagnosis and treatment,
vast differences in melanoma burden still exist between populations. Comparative
data can highlight these differences and lead to focused efforts to reduce the bur-
den of melanoma.
Objectives To assess global, regional and national melanoma incidence, mortality
and disability-adjusted life year (DALY) estimates from the Global Burden of Dis-
ease Study 2015.
Methods Vital registration system and cancer registry data were used for melanoma
mortality modelling. Incidence and prevalence were estimated using separately mod-
elled mortality-to-incidence ratios. Total prevalence was divided into four disease
phases and multiplied by disability weights to generate years lived with disability
(YLDs). Deaths in each age group were multiplied by the reference life expectancy to
generate years of life lost (YLLs). YLDs and YLLs were added to estimate DALYs.
Results The five world regions with the greatest melanoma incidence, DALY and
mortality rates were Australasia, North America, Eastern Europe, Western Europe
and Central Europe. With the exception of regions in sub-Saharan Africa, DALY
and mortality rates were greater in men than in women. DALY rate by age was
highest in those aged 75–79 years, 70–74 years and ≥ 80 years.
Conclusions The greatest burden from melanoma falls on Australasian, North Amer-
ican, European, elderly and male populations, which is consistent with previous
investigations. These substantial disparities in melanoma burden worldwide high-
light the need for aggressive prevention efforts. The Global Burden of Disease
Study results can help shape melanoma research and public policy.
What’s already known about this topic?
• Melanoma incidence and mortality has been assessed in the past for individual
countries or world regions.
© 2017 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
134 British Journal of Dermatology (2017) 177, pp134–140
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
What does this study add?
• As part of the Global Burden of Disease Study, melanoma burden was estimated at
the global, regional and country level for incidence, mortality, prevalence, years
lived with disability, years of life lost and disability-adjusted life years.
• These estimates can be used to guide prevention and treatment strategies, as well
as resource allocation.
The landscape of melanoma, the most deadly skin cancer,
has changed dramatically in the twenty-first century. Preven-
tion, including increased public education and awareness,
early detection, genetic testing and substantial improvements
in advanced melanoma therapies are examples of recent pro-
gress. To describe fully the effect of a disease on a popula-
tion, metrics beyond incidence and mortality are needed.1
One approach is to estimate disability-adjusted life years
(DALYs), which combine morbidity and mortality metrics.2
For reference, one DALY is equivalent to 1 year of healthy
life lost. Prior studies have applied DALYs to study mela-
noma burden among other cancers in world regions and also
within individual countries.3,4 However, an up-to-date large-
scale effort to quantify the comprehensive burden of mela-
noma, as well as the diversity of causes on global and
national scales, is warranted. DALYs, in addition to standard
metrics such as incidence, mortality and prevalence are esti-
mated as part of the Global Burden of Disease Study (GBD).
The GBD is a systematic scientific effort to quantify the com-
parative magnitude of health loss resulting from diseases,
injuries and risk factors according to age, sex and geography
over time.5,6 For GBD 2015, the burden of 310 diseases,
including melanoma, was estimated.7 This study presents the
GBD 2015 melanoma incidence, mortality and DALY esti-
mates by sex for 21 world regions encompassing 195 coun-
tries and territories.
Materials and methods
Detailed GBD methodology is published elsewhere.2,8,9 A
brief overview of the specific melanoma estimation strategy
is presented here. Data sources include vital registration sys-
tems and cancer registry incidence data that were first trans-
formed to mortality estimates using separately estimated
mortality-to-incidence (MI) ratios. Briefly, incidence and
mortality data were matched by cancer, age, sex, year and
location. Multiple logit random effects models were tested,
comparing mean MI predictions and mean root-mean-
squared error to determine a final model output. After
removing outliers (data points that unrealistically influenced
the model) and space-time smoothing (spatiotemporal
regression to smooth residuals over space, time and age), a
Gaussian process regression was performed, which interpo-
lates nonlinear trends. Final MI ratios with 95% confidence
intervals (CIs) were generated by back-transforming 1000
draws from the posterior distribution.8 Cancer registry data
were obtained either by contacting cancer registries directly
or accessing publicly available data sources such as CI5
(Cancer Incidence in Five Countries).10 Data sources were
used as input into a cause-of-death modelling tool (i.e.
cause-of-death ensemble model approach), which combines
many possible models into an ensemble with more accurate
trends and smaller error than a single model.6,11 To
improve estimates for melanoma mortality in areas with
sparse data, the following covariates were used: income per
capita, years of education per capita, latitude, smoking,
alcohol intake, animal fat consumption, fruit and vegetable
consumption, mean body mass index and diabetes preva-
lence. Melanoma mortality together with all other single-
cause estimates were adjusted to fit into the separately
estimated all-cause mortality. For melanoma incidence esti-
mates, final melanoma mortality estimates were divided by
the MI ratios.
The 10-year prevalence was estimated using melanoma inci-
dence and survival estimates. Melanoma survival was estimated
by transforming MI ratios into an access-to-care variable and
scaling each incidence cohort between a ‘best case’ and ‘worst
case’ survival.8 The ‘best case’ survival curve was derived from
Surveillance, Epidemiology, and End Results (SEER) pro-
gramme 2010 data, while the ‘worst case’ survival curve was
derived from the 1950 U.S. Mortality Files and Cancer Survival
in Africa, Asia, the Caribbean and Central America (SurvCan).
Prevalence was divided into the following four disease phases:
(i) diagnosis and treatment, (ii) remission, (iii) metastatic and
(iv) terminal. A constant duration for the diagnosis and treat-
ment phase (2 months),12 metastatic phase (718 months)13
and terminal phase (1 month) was used for all ages, countries
and times, owing to a lack of data regarding stage distribution
and treatment in a majority of countries. Prevalence of remis-
sion was estimated by subtracting the sum of the remaining
phases from the total prevalence by location, age, sex and
year. Prevalence estimates were multiplied by distinct disabil-
ity weights, derived from population surveys and an open
access web-based survey, to generate years lived with disabil-
ity (YLDs).14 Years of life lost (YLLs) were calculated by mul-
tiplying the number of deaths in each age group by the
corresponding standard life expectancy. The normative stan-
dard life expectancy was based on the lowest age-specific
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mortality rate from any cause in each year from all countries
with populations greater than 2 million people. The normative
standard life expectancy for GBD 2015 was 8659 years.15
YLD and YLL estimates were added for each age group, loca-
tion, sex and year to yield DALYs. All estimates were produced
with 95% uncertainty intervals. Melanoma incidence, DALYs
and mortality are reported for 195 countries represented by
21 world regions, both sexes and 14 age groups, ranging
from 15 to ≥ 80 years (see Table 1 for GBD regions and rep-
resented countries).
Results
The global incidence of melanoma in 2015 was 351 880 cases
(95% CI 281 633–445 036) with an age-standardized rate of
five cases per 100 000 persons (95% CI 4–7). Melanoma was
responsible for 1 596 262 global DALYs (95% CI 1 293 447–
1 982 679) with an age-standardized rate of 23 DALYs per
100 000 persons (95% CI 18–28). Melanoma was also
responsible for 59 782 global deaths (95% CI 47 602–
72 671) with an age-standardized rate of one death per
100 000 persons (95% CI 07–1). With 100% representing
total burden from all conditions studied by GBD 2015, mela-
noma was responsible for 0065% of all DALYs.
The five world regions with the greatest incidence rates
were Australasia [54 (95% CI 41–78)], North America [21
(95% CI 16–31)], Western Europe [16 (95% CI 11–20)],
Central Europe [8 (95% CI 7–11)] and Eastern Europe [8
(95% CI 6–10)] (Table 2). Similarly, these were the five
world regions with the greatest DALY rates: Australasia [152
(95% CI 112–221)], North America [66 (95% CI 51–100)],
Eastern Europe [65 (95% CI 51–85)], Western Europe [58
(95% CI 41–76)] and Central Europe [58 (95% CI 44–73)].
Mortality rates were also highest in these five regions: Aus-
tralasia [6 (95% CI 4–8)], North America [2 (95% CI 2–3)],
Eastern Europe [2 (95% CI 2–3)], Central Europe [2 (95% CI
2–3)] and Western Europe [2 (95% CI 1–3)].
Of the 195 countries studied, the five highest age-standar-
dized incidence rates were in New Zealand [54 (95% CI 39–
73)], Australia [54 (95% CI 41–78)], Norway [26 (95% CI
18–32)], Sweden [26 (95% CI 20–35)] and the Netherlands
[25 (95% CI 17–30)]. The top-five highest age-standardized
DALY rates were in New Zealand [165 (95% CI 119–228)],
Australia [149 (95% CI 111–221)], Norway [107 (95% CI
Table 1 Global Burden of Disease Study region classifications
Global Burden of
Disease Study region Countries represented
East Asia China, North Korea, Taiwan
Oceania American Samoa, Federated States of Micronesia, Fiji, Guam, Marshall Islands, Northern Mariana Islands, Papua
New Guinea, Samoa, Solomon Islands, Tonga, Vanuatu
Southeast Asia Cambodia, Indonesia, Laos, Malaysia, Maldives, Mauritius, Myanmar, Philippines, Sri Lanka, Seychelles,
Thailand, Timor-Leste, Vietnam
South Asia Bangladesh, Bhutan, India, Nepal, Pakistan
Central Asia Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Mongolia, Tajikistan, Turkmenistan, Uzbekistan
Central Europe Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Macedonia, Poland, Romania,
Serbia, Slovakia, Slovenia
Eastern Europe Belarus, Estonia, Latvia, Lithuania, Moldova, Russia, Ukraine
North Africa and Middle East Afghanistan, Algeria, Bahrain, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Palestine, Oman,
Qatar, Saudi Arabia, Sudan, Syria, Tunisia, Turkey, United Arab Emirates, Yemen
Western Sub-Saharan Africa Benin, Burkina Faso, Cameroon, Cape Verde, Chad, Cote d’Ivoire, The Gambia, Ghana, Guinea, Guinea-Bissau,
Liberia, Mali, Mauritania, Niger, Nigeria, Sao Tome and Principe, Senegal, Sierra Leone, Togo
Southern Sub-Saharan Africa Botswana, Lesotho, Namibia, South Africa, Swaziland, Zimbabwe
Eastern Sub-Saharan Africa Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mozambique, Rwanda, Somalia,
South Sudan, Tanzania, Uganda, Zambia
Central Sub-Saharan Africa Angola, Central African Republic, Congo, Democratic Republic of the Congo, Equatorial Guinea, Gabon
Tropical Latin America Brazil, Paraguay
Andean Latin America Bolivia, Ecuador, Peru
Central Latin America Colombia, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Venezuela
Caribbean Antigua and Barbuda, The Bahamas, Barbados, Belize, Bermuda, Cuba, Dominica, Dominican Republic,
Grenada, Guyana, Haiti, Jamaica, Puerto Rico, Saint Lucia, Saint Vincent and the Grenadine, Suriname,
Trinidad and Tobago, Virgin Islands
Western Europe Andorra, Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy,
Luxembourg, Malta, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, U.K.
Southern Latin America Argentina, Chile, Uruguay
North America Canada, U.S.A.
Asia Pacific Brunei, Japan, Singapore, South Korea
Australasia Australia, New Zealand
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70–133)], the Netherlands [98 (95% CI 65–120)] and Swe-
den [97 (95% CI 71–135)] (Fig. 1). Age-standardized mortal-
ity rates were also highest in New Zealand [6 (95% CI 4–8)],
Australia [6 (95% CI 4–8)], Norway [4 (95% CI 3–5)], Swe-
den [4 (95% CI 3–5)] and the Netherlands [3 (95% CI 2–4)].
The global age-standardized DALY rates resulting from mel-
anoma were 27 (95% CI 18–38) in male patients and 19
(95% CI 17–21) in female patients. DALY rates were greater
in men than in women in all world regions with the excep-
tion of Central, Eastern and Western sub-Saharan Africa, where
melanoma DALY rates were greater in women (Fig. 2). Differ-
ences in melanoma mortality rate by sex followed a similar
pattern to DALY rates (Fig. 3). For DALY rate by age, the fol-
lowing groups demonstrated the highest rates: 75–79 years,
70–74 years and ≥ 80 years (Table 3).
Discussion
We reveal that the greatest burden from melanoma falls on
New Zealand, Australia, Europe, the elderly and male popula-
tions. Reasons for the disproportionate burden of melanoma
in Australasia have been well documented and include a pre-
dominantly fair-skinned population, living with high ambient
solar ultraviolet (UV) radiation levels, and having a cultural
emphasis on tanning.16 A similar study investigating burden
of disease metrics for 27 cancer groups in 12 world regions
found the highest DALY rates from melanoma in Australia and
New Zealand, followed by Northern Europe, North America,
Western Europe, Southern Europe and Eastern Europe.3 These
findings agree well with those of our current study. In addi-
tion, the burden of melanoma on many regions of Europe,
particularly Western Europe, has been recognized. A prior
study in the Netherlands found that from 1991 to 2010 there
were 96% and 75% increases in melanoma DALYs in men and
women, respectively.4 Specific to Scandinavian populations,
despite living with low ambient UV, the higher incidence of
melanoma may be predominantly attributed to a high-risk
phenotype (fair skin, hair and eye colour), combined with a
tanning culture favouring high levels of UV exposure with
sunny holidays and indoor tanning.17–19 Regarding age differ-
ences, the higher DALY rates observed in elderly populations
are likely a result of peak incidence rates owing to prolonged
lifetime cumulative risk factors.20 Sex differences in melanoma
incidence and mortality are well documented, as men tend to
have worse sun protection behaviours and reduced skin
screening, as well as biological differences in tumours.21
It is of interest to compare the differences in melanoma
burden between three high-income countries, i.e. Australia,
New Zealand and the U.S.A., particularly in regard to national
policy efforts. Of the 195 countries, New Zealand and Aus-
tralia ranked first and second, respectively, while the U.S.A.
was ranked 18th in melanoma DALY rates. Remarkably, the
age-standardized melanoma DALY rate in New Zealand was
almost 25 times greater than that in the U.S.A. The burden of
melanoma in the Australasian region can at least partly be
attributed to predominantly fair-skinned populations with
high ambient UV and cultural habits of outdoor recreation
and sun tanning.22 However, Australia has undertaken aggres-
sive and comprehensive skin cancer awareness campaigns for
over three decades to reduce the burden of skin cancer.16,23
Following the International Agency for Research on Cancer
classification of UV-emitting tanning devices as class I
Table 2 Age-standardized incidence, disability-adjusted life year (DALY) and mortality rates for 21 world regions
Region Incidence rate (95% CI) DALY rate (95% CI) Mortality rate (95% CI)
Australasia 541170 (407429–778116) 1515096 (1121229–2209776) 56255 (40817–79069)
North America 210783 (161285–309608) 660197 (507840–997413) 22992 (16701–33432)
Eastern Europe 78326 (62571–98118) 652106 (509055–846727) 22749 (18017–29094)
Western Europe 156651 (113721–201230) 582175 (410517–758866) 20665 (14470–25908)
Central Europe 83560 (64831–105992) 577440 (435435–726766) 20795 (15600–25592)
Southern Sub-Saharan Africa 63628 (49125–78282) 336285 (259907–390645) 14286 (11162–16328)
Southern Latin America 52630 (38651–71943) 325423 (235926–451229) 12776 (09299–17071)
Tropical Latin America 55221 (41212–65629) 276028 (209512–305295) 10908 (08430–11969)
Central Asia 36565 (31654–45980) 203091 (179108–255949) 07797 (06910–09922)
Central Latin America 32885 (24786–43273) 177484 (133281–236114) 07234 (05479–09377)
Andean Latin America 28237 (23764–35472) 166716 (144629–209201) 07467 (06502–09372)
Oceania 25894 (18818–38080) 158802 (113658–242364) 03597 (04788–09624)
Caribbean 28244 (24326–36637) 146916 (127388–188543) 05985 (05202–07801)
Central Sub-Saharan Africa 21923 (14123–32689) 126024 (84114–197562) 04690 (03047–06881)
Eastern Sub-Saharan Africa 21221 (16561–26536) 115941 (90618–144732) 04628 (03671–05796)
Western Sub-Saharan Africa 22212 (17434–30505) 106301 (85621–147869) 04833 (03906–06635)
North Africa and Middle East 16660 (14458–22201) 104575 (92637–143409) 04237 (03753–05721)
East Asia 14307 (10586–17655) 102859 (75003–115445) 03731 (02953–04085)
Southeast Asia 13100 (10986–17015) 92136 (78837–119697) 03352 (02855–04343)
Asia Pacific 07130 (05524–09494) 77359 (57688–108982) 03089 (02295–04173)
South Asia 11088 (08943–14254) 64210 (55115–83923) 02313 (02014–02954)
CI, confidence interval.
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‘carcinogenic to humans’, Australia became the second nation
after Brazil to enact a nationwide ban on commercial tanning
beds.24,25 In contrast, New Zealand has lagged behind Aus-
tralia in skin cancer prevention efforts and implementation of
protective behaviours. Tanning beds are not currently partially
or fully banned and a recent study revealed 176 businesses
nationwide offering commercial tanning beds to consumers.26
In addition, regarding the paediatric and adolescent popula-
tions, which spend high-UV hours at school, multiple investi-
gations found that only 50% of New Zealand schools had an
established sun policy behaviour and that sun barriers such as
sunscreen and hats were poorly used at outdoor school activi-
ties.27–29 Researchers from these studies note that while multi-
ple nongovernmental charities have been actively involved in
Fig 1. World map of age-standardized
disability-adjusted life year rates per 100 000
persons from melanoma, both sexes.
Fig 2. Age-standardized melanoma disability-adjusted life year (DALY) rates in 21 world regions by sex.
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sun protection efforts, there is a need for New Zealand gov-
ernment collaboration to promote universal sun awareness and
protection policies.28
Regarding national melanoma treatment guidelines, a
review article comparing the U.S.A., Canada, Europe, Australia
and New Zealand, found that the Australian Cancer Network
(ACN), responsible for guideline generation in Australia and
New Zealand, produced the strictest follow-up recommenda-
tions for patients with melanoma of any stage, including the
use of ultrasound in surveillance of lymph node recurrence.30
While the National Comprehensive Cancer Network (NCCN)
does not issue a consensus on routine melanoma screening,
the ACN has recommended against population-based screen-
ing. The ACN and NCCN generally share recommendations
regarding biopsy and excisions guidelines.30
The GBD relies on the premise that estimates based on
high-quality analyses and prediction models, while imperfect,
are better than no data at all. Estimations for areas lacking can-
cer data are dependent on covariate selection and regional pat-
terns. This highlights the importance of a global effort to
improve vital registration systems and cancer registries. There
are a number of limitations to the use of the DALY in regard
to melanoma. As mentioned above, because the stage of diag-
nosis is not incorporated, melanoma DALYs may change with
time, as increased early detection leads to a higher proportion
of detected melanomas at an early stage. Similarly, with recent
progress in advanced melanoma treatment and prognosis, the
disability from melanoma is likely to change over time, mak-
ing temporal DALY comparisons difficult.
A recent report investigated DALYs from melanoma by stage
among a large cohort of patients from the Belgian Cancer Reg-
istry.31 Melanoma mortality, expressed as YLLs, was divided
among the melanoma stages as follows: 28% stage I, 33%
Fig 3. Age-standardized melanoma mortality rates in 21 world regions by sex.
Table 3 Global melanoma disability-adjusted life year (DALY) rate per
100 000 persons over human lifespan, ages ranging from 15 to
≥ 80 years, both sexes
Age range
(years)
DALYs per 100 000 persons
(95% uncertainty interval)
15–19 26 (23–32)
20–24 49 (42–61)
25–29 83 (71–103)
30–34 125 (106–156)
35–39 187 (159–240)
40–44 265 (221–332)
45–49 327 (272–409)
50–54 463 (375–596)
55–59 576 (459–728)
60–64 660 (512–837)
65–69 684 (524–847)
70–74 840 (641–1031)
75–79 847 (642–1018)
≥ 80 840 (645–965)
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stage II, 262% stage III and 13% stage IV. Over half of mela-
noma morbidity, expressed as YLDs, was attributed to melano-
mas with node metastases, while 35% was attributed to
localized melanomas and 13% to melanoma with distant
metastases. For GBD 2015, stage of diagnosis was not incorpo-
rated into the GBD disability estimates. Melanoma stage of
diagnosis could be included in future GBD 2015 data for
high-income countries. Another area of consideration in future
GBD iterations is the particular burden imposed by early
detection and preventative activities. Regardless of its short-
comings, the GBD provides high-quality, comparative esti-
mates of melanoma burden. As GBD results are now produced
on an annual basis, the global collaboration continually works
to improve existing estimates and incorporate new studies.
Epidemiological assessments such as the GBD have the poten-
tial to influence research and public policy regarding mela-
noma pathogenesis, prevention, diagnosis and treatment.
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